Scalper1 News
Recent biotech IPO NeuroDerm (NDRM) on Tuesday bounced back from its flop stock market debut last month after it reported positive midstage trial results for its Parkinson’s disease candidate, with shares jumping more than 70%. NeuroDerm said ND0612H, a high-dose combination of standard Parkinson’s drugs levodopa and carbidopa delivered through a belt-worn pump, had significantly increased plasma levodopa levels in patients. The company believes Scalper1 News
Scalper1 News